P/E spoločnosti Abeona Therapeutics Inc
Aká je hodnota metriky P/E spoločnosti Abeona Therapeutics Inc?
Hodnota metriky P/E spoločnosti Abeona Therapeutics Inc je 0.00
Aká je definícia metriky P/E?
P/E ratio je koeficient daný pomerom ceny akcie a príjmu spoločnosti na akciu za posledných 12 mesiacov.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/E spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Abeona Therapeutics Inc
Čomu sa venuje spoločnosť Abeona Therapeutics Inc?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Firmy s metrikou p/e podobnou spoločnosti Abeona Therapeutics Inc
- Hodnota metriky P/E spoločnosti Richland Resources International je N/A
- Hodnota metriky P/E spoločnosti Safeplus International je N/A
- Hodnota metriky P/E spoločnosti China Yanyuan Yuhui Natl Ed Grp je N/A
- Hodnota metriky P/E spoločnosti Acusphere je N/A
- Hodnota metriky P/E spoločnosti American Oriental Bioengineering je N/A
- Hodnota metriky P/E spoločnosti Gourmet Provisions International je N/A
- Hodnota metriky P/E spoločnosti Abeona Therapeutics Inc je 0.00
- Hodnota metriky P/E spoločnosti SEL Manufacturing je 0.00
- Hodnota metriky P/E spoločnosti China Zhong Qi Hldgs je 0.00
- Hodnota metriky P/E spoločnosti MedSmart je 0.00
- Hodnota metriky P/E spoločnosti Panbela Therapeutics je 0.00
- Hodnota metriky P/E spoločnosti Epic je 0.00
- Hodnota metriky P/E spoločnosti 2574 je 0.00